JP Morgan Maintains Overweight on CytomX Therapeutics, Raises Price Target to $12
Benzinga Newsdesk 22 minutes ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $11 to $12.
JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $11 to $12.